Science community gets insight into world-leading drug development


13-12-2011

Members of One Nucleus, the organisation for international life science and healthcare companies based at Granta Park, Cambridge, were given an insight into the work of one of the world’s leading biotechnology companies when, member company, MedImmune hosted a One Nucleus networking event at its Riverside office facility in Granta Park.

The theme for the evening was “Working with MedImmune” and consisted of presentations from MedImmune’s scientific and clinical staff, providing a fascinating overview of the Company, its range of technologies, and the diverse therapeutic areas being targeted.

Headquartered in Gaithersburg, Maryland in the United States, MedImmune has had a presence on Granta Park since 2001. Reflecting its key research and development role within MedImmune’s global organisation, MedImmune’s facilities at Granta Park have continued to expand and the Company now has over 500 staff supporting the development of new biologic treatments. Over the past decade, the Company has expanded from one 20,000 sq ft laboratory building to more than 200,000 sq ft of laboratory and office buildings located within Granta Park.

The latest expansion, which took place last year, has seen over 50 scientists and medical staff comprising the Company’s Clinical Development Teams move into a new 20,000 sq ft office facility in Granta Park’s Riverside complex.

MedImmune’s Director of Clinical Development, Ed Piper, explained that, as the global biologics arm of AstraZeneca, MedImmune is at the forefront of groundbreaking biotechnology research and development, and that MedImmune Cambridge, with its long history and culture of innovation, plays a central research and development role within MedImmune’s global organisation.

“Collaborating within international teams, our research and development groups based at Granta Park are focused on delivering the medicines of tomorrow through a range of innovative antibody, vaccine, and protein technologies,” he said.

“We have one of the largest pipelines in the industry, with currently over 100 research projects and clinical product candidates in our portfolio. Key areas of focus include infectious diseases, inflammation, cancer, and autoimmune and respiratory diseases. In addition, we’re continuing to build on our leadership position in neuroscience, and cardiovascular and gastrointestinal diseases.”

MedImmune’s Director of Oncology, Matthew McCourt, also spoke about the importance of Granta Park for MedImmune in offering it the right working environment and amenities to attract and retain the best scientists, and also the opportunity to network with other organisations and be part of a vibrant and collaborative science community.

He commented: “As well as working with One Nucleus itself, being based at Granta Park has given us the opportunity to collaborate with other organisations in projects such as scientific poster events, science fairs, and community outreach to schools and universities. We see this as an important part of our work.”


 

To read more information, click here.

BioMed Realty has been part of Cambridge's world-class life science community since the acquisition of Granta Park in 2012. Granta Park is a 477,230 square foot business estate in one of the most reconised areas for science success globally and is home to leading companies, including Sosei Heptares, Astrazeneca, Illumina, PPD Global, and One Nucleus.

BioMed Realty